

Financial news for SGM0 dated on 2020-05-11: Sangamo Therapeutics Q1 EPS \$(0.370) Misses \$(0.290) Estimate, Sales \$13.076M Miss \$22.740M Estimate

Financial news for SGM0 dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for SGM0 dated on 2020-04-21: Mogrify And Sangamo Announce Collaboration And Exclusive License Agreement For Mogrify's iPSC- And ESC-Derived Regulatory T Cells

Financial news for SGM0 dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for SGM0 dated on 2020-04-07: 15 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for SGM0 dated on 2020-04-07: 22 Stocks Moving in Tuesday's Pre-Market Session

Financial news for SGM0 dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for SGM0 dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for SGM0 dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for SGM0 dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for SGM0 dated on 2020-02-28: 86 Stocks Moving In Friday's Mid-Day Session

Financial news for SGM0 dated on 2020-02-28: Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results and sales up from last year. The company also announced a global collaboration with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, and Neurimuscular.

Financial news for SGM0 dated on 2020-02-28: 50 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for SGM0 dated on 2020-02-28: 46 Stocks Moving in Friday's Pre-Market Session

Financial news for SGM0 dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for SGM0 dated on 2020-02-28: Sangamo Therapeutics Q4 EPS \$(0.04) Beats \$(0.33) Estimate, Sales \$54.9M Up From \$26.8M YoY

Financial news for SGM0 dated on 2020-02-27: Biogen And Sangamo Announce Global Collaboration To Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular And Other Neurological Diseases; Biogen To Pay Sangamo \$350M Upfront, Sangamo Eligible For Up To \$2.37B In Milestones

Financial news for SGM0 dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for SGM0 dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for SGM0 dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for SGM0 dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for SGM0 dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for SGM0 dated on 2020-01-28: 43 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for SGM0 dated on 2020-01-28: Gene-editing/sequencing stocks trading higher following finalization of national coverage decision by Centers for Medicare &

Medicaid Services related to next-gen sequencing.

Financial news for SGM0 dated on 2019-12-23: Sangamo Therapeutics shares are trading higher. The company announced early completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy IND, earning a \$25 million milestone payment.

Financial news for SGM0 dated on 2019-12-23: Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned \$25 Million Milestone Payment

Financial news for SGM0 dated on 2019-12-17: Sangamo To Provide Updates At R&D Event Beginning At 8:00 a.m. ET; Co. Will Introduce New Gene Therapy And Genome Regulation Programs For Clinical Development With IND Targets In 2021 And 2022

Financial news for SGM0 dated on 2019-12-12: 13 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2019-12-11: 66 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2019-12-10: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SGM0 dated on 2019-12-10: Sangamo Therapeutics shares are trading lower on continued momentum after the company announced preliminary results from 3 patients in its Phase 1/2 study of ST-400.

Financial news for SGM0 dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2019-12-09: Sangamo Therapeutics shares are trading lower after the company announced preliminary results from 3 patients in its Phase 1/2 study of ST-400.

Financial news for SGM0 dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2019-12-09: Sangamo Gives Preliminary Results from 3 Patients in its Phase 1/2 Study of ST-400

Financial news for SGM0 dated on 2019-12-07: Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment at ASH 2019

Financial news for SGM0 dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2019-12-03: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SGM0 dated on 2019-12-03: The Gene Therapy Names Moving On The Audentes Buyout Deal

Financial news for SGM0 dated on 2019-12-03: Sangamo Therapeutics shares are trading higher in sympathy with Audentes Therapeutics after the company announced it will be acquired by Astellas Pharma for \$60 per share in cash.

Financial news for SGM0 dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for SGM0 dated on 2019-11-19: Sangamo Announces UK Authorization Of Phase 1/2 Clinical Trial Evaluating The CAR-Treg Cell Therapy TX200 For Kidney Transplantation

Financial news for SGM0 dated on 2019-11-08: Sangamo Therapeutics Announces New Scientific Advisory Board

Financial news for SGM0 dated on 2019-11-07: Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for SGM0 dated on 2019-11-06: Sangamo Therapeutics Q3 EPS \$(0.24) Beats \$(0.34) Estimate, Sales \$21.958M Beat \$12.16M Estimate

Financial news for SGM0 dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for SGM0 dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for SGM0 dated on 2019-11-01: Sangamo Therapeutics Names Sung Lee CFO

Financial news for SGM0 dated on 2019-08-26: 16 Healthcare Stocks Moving In Monday's

Pre-Market Session

Financial news for SGMO dated on 2019-07-09: A Look At Benzinga Pro's Most-Searchd Tickers For July 9, 2019

Financial news for SGMO dated on 2019-07-09: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Tuesday, July 9, 2019

Financial news for SGMO dated on 2019-07-08: A Look At Benzinga Pro's Most-Searchd Tickers For July 8, 2019

Financial news for SGMO dated on 2019-07-08: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for SGMO dated on 2019-07-08: Why Is Sangamo Therapeutics Moving?

Financial news for SGMO dated on 2019-07-08: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Monday, July 8, 2019

Financial news for SGMO dated on 2019-07-08: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for SGMO dated on 2019-07-08: Sangamo Therapeutics shares are trading higher after the company presented data from its Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A over the weekend.

Financial news for SGMO dated on 2019-07-06: Sangamo, Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Financial news for SGMO dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for SGMO dated on 2019-07-01: Sangamo Therapeutics Reports Nature Medicine Publication Detailing Activity Of Disease Allele-Selective Zinc Finger Proteins In Preclinical Models Of Huntington's Disease

Financial news for SGMO dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for SGMO dated on 2019-06-25: Sangamo Therapeutics Option Alert: Jul 19 \$10 Calls Sweep (38) near the Ask: 782 @ \$0.601 vs 2211 OI; Earnings 8/7 After Close [est] Ref=\$9.77

Financial news for SGMO dated on 2019-06-21: Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019

Financial news for SGMO dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for SGMO dated on 2019-05-10: 82 Biggest Movers From Yesterday

Financial news for SGMO dated on 2019-05-09: 71 Stocks Moving In Thursday's Mid-Day Session

Financial news for SGMO dated on 2019-05-09: Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for SGMO dated on 2019-05-08: Sangamo BioSciences Q1 EPS \$(0.41) Misses \$(0.25) Estimate, Sales \$8.071M Miss \$22.82M Estimate

Financial news for SGMO dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for SGMO dated on 2019-04-05: 52 Biggest Movers From Yesterday

Financial news for SGMO dated on 2019-04-04: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for SGMO dated on 2019-04-04: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGMO dated on 2019-04-04: Sangamo Therapeutics Prices 11M Shares At \$11.50/Share

Financial news for SGMO dated on 2019-04-04: The Daily Biotech Pulse: Recro

Restructures, Biotechs Raise Proceeds In Drove, Silk Road, NGM Biopharma To Debut

Financial news for SGM0 dated on 2019-04-04: 8 Stocks To Watch For April 4, 2019

Financial news for SGM0 dated on 2019-04-03: Hearing Sangamo Just-Announced Offering Will Be Priced At \$11.50/Share For Offering Size Of \$115M

Financial news for SGM0 dated on 2019-04-03: Sangamo Therapeutics Reports Proposed Common Stock Offering; Size No Disclosed

Financial news for SGM0 dated on 2019-04-03: Benzinga Pro's Top 10 Most Searched Tickers For Morning Of Wed., Apr. 3, 2019

Financial news for SGM0 dated on 2019-04-03: 54 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2019-04-02: Mid-Afternoon Market Update: ADMA Biologics Jumps On FDA Nod For Immunodeficiency Therapy; Evoke Pharma Shares Plummet

Financial news for SGM0 dated on 2019-04-02: Sangamo Soars Amid Multiple Development Pipeline Updates

Financial news for SGM0 dated on 2019-04-02: Mid-Day Market Update: Crude Oil Up Over 1%; Apyx Medical Shares Slide

Financial news for SGM0 dated on 2019-04-02: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for SGM0 dated on 2019-04-02: Hearing Sangamo Price Target Raised From \$24 To New Street High Of \$34 By Wells Fargo

Financial news for SGM0 dated on 2019-04-02: Mid-Morning Market Update: Markets Edge Lower; Walgreens Misses Q2 Views

Financial news for SGM0 dated on 2019-04-02: Sangamo Therapeutics shares are trading higher after the company announced positive Phase 1/2 interim data for its investigational Hemophilia gene therapy.

Financial news for SGM0 dated on 2019-04-02: UPDATE: Safety Monitoring Committee Recommended Cohort Expansion At The 3E13 Vg/Kg Dose Of SB-525

Financial news for SGM0 dated on 2019-04-02: Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy; SB-525 Was Well Tolerated And Demonstrated A Dose-Dependent Increase In Factor VIII (FVIII) Levels

Financial news for SGM0 dated on 2019-04-01: Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update

Financial news for SGM0 dated on 2019-03-29: Sangamo Therapeutics Option Alert: Apr 18 \$10 Calls Sweep (2) near the Ask: 1886 @ \$0.3 vs 2249 OI; Earnings 5/7 Before Open [est] Ref=\$9.4539

Financial news for SGM0 dated on 2019-03-29: UPDATE: Sangamo Says 'Tau was reduced by greater than 80% in the brains of mice and nonhuman primates'

Financial news for SGM0 dated on 2019-03-29: Sangamo Highlights Preclinical Data For ZFP-TFs Showing 'Significant' Reduction In Tau Expression With Gene Regulation Technology

Financial news for SGM0 dated on 2019-03-08: Sangamo Therapeutics Earlier Highlighted Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing

Financial news for SGM0 dated on 2019-03-04: 81 Biggest Movers From Friday

Financial news for SGM0 dated on 2019-03-01: Sangamo Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for SGM0 dated on 2019-03-01: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for SGM0 dated on 2019-02-28: Sangamo Therapeutics Q4 EPS \$(0.18) Beats \$(0.21) Estimate, Sales \$26.837M Beat \$22.51M Estimate

Financial news for SGM0 dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for SGM0 dated on 2019-02-25: Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for \$114.50

per share in cash.

Financial news for SGMO dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for SGMO dated on 2019-02-20: Sangamo Announces FDA Acceptance Of IND Application For ST-920 Gene Therapy Candidate For Fabry Disease

Financial news for SGMO dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for SGMO dated on 2019-02-08: 72 Biggest Movers From Yesterday

Financial news for SGMO dated on 2019-02-07: Mid-Afternoon Market Update: Dow Down 1.1%; Chipotle Shares Jump Following Upbeat Q4 Results

Financial news for SGMO dated on 2019-02-07: Sangamo Fails To Impress Investors With Genome Editing Studies

Financial news for SGMO dated on 2019-02-07: Sangamo Shares Tick Higher Over \$8 Level As Hearing Wells Fargo Issued Mid-Day Defense On Stock/Co.

Financial news for SGMO dated on 2019-02-07: 54 Stocks Moving In Thursday's Mid-Day Session

Financial news for SGMO dated on 2019-02-07: Mid-Day Market Update: Crude Oil Down Over 3%; Solid Biosciences Shares Plunge

Financial news for SGMO dated on 2019-02-07: Sangamo Therapeutics shares are trading lower after the company reported its SB-318 zinc finger nuclease genome editing product did not appear to show a clinical benefit in a Phase 1/2 trial.

Financial news for SGMO dated on 2019-02-07: 'First attempt at genome editing in U.S. patients produces disappointing -- and sobering -- results' -STAT News

Financial news for SGMO dated on 2019-02-07: Sangamo Therapeutics Shares Halted On Circuit Breaker; Down 12.2%

Financial news for SGMO dated on 2019-02-07: Sangamo Therapeutics Reports Results Of Phase 1/2 EMPOWERS Study Of SB-318 Zinc Finger Nuclease

Financial news for SGMO dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

Financial news for SGMO dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for SGMO dated on 2019-01-18: Jim Cramer Advises His Viewers On Brink's, Medtronic And More

Financial news for SGMO dated on 2019-01-10: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGMO dated on 2019-01-10: 56 Biggest Movers From Yesterday

Financial news for SGMO dated on 2018-12-17: Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B

Financial news for SGMO dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for SGMO dated on 2018-11-15: 76 Biggest Movers From Yesterday

Financial news for SGMO dated on 2018-11-14: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for SGMO dated on 2018-11-14: Sangamo Therapeutics shares down 16.0% following downgrade from JP Morgan; Analysts cited an 'undefined catalyst outlook'

Financial news for SGMO dated on 2018-11-14: 8 Biggest Price Target Changes For Wednesday

Financial news for SGMO dated on 2018-11-14: JP Morgan Maintains Neutral on Sangamo Therapeutics, Lowers Price Target to \$11

Financial news for SGMO dated on 2018-11-14: 33 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGMO dated on 2018-11-14: JP Morgan Downgrades Sangamo Therapeutics to Neutral, Lowers Price Target to \$11

Financial news for SGMO dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for SGMO dated on 2018-11-12: 85 Biggest Movers From Friday

Financial news for SGMO dated on 2018-11-09: 68 Stocks Moving In Friday's Mid-Day Session

Financial news for SGMO dated on 2018-11-09: Sangamo Therapeutics shares are trading lower after the company announced it will not present initial SB-525 data at the ASH18 conference in December.

Financial news for SGMO dated on 2018-11-09: Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 8, 2018

Financial news for SGMO dated on 2018-11-09: Benzinga's Top Upgrades, Downgrades For November 9, 2018

Financial news for SGMO dated on 2018-11-09: Guggenheim Downgrades Sangamo Therapeutics to Neutral

Financial news for SGMO dated on 2018-11-08: Sangamo BioSciences, Inc. Q3 EPS \$(0.13) Beats \$(0.15) Estimate, Sales \$23.562M Miss \$26.96M Estimate

Financial news for SGMO dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for SGMO dated on 2018-09-05: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Histogenics Shares Plunge

Financial news for SGMO dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for SGMO dated on 2018-09-05: Mid-Day Market Update: NASDAQ Down Over 100 Points; ProQR Therapeutics Shares Surge

Financial news for SGMO dated on 2018-09-05: Mid-Morning Market Update: Markets Open Lower; HD Supply Earnings Top Expectations

Financial news for SGMO dated on 2018-09-05: Sangamo Shares Sink After Data Release For Gene Editing Product Candidate

Financial news for SGMO dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for SGMO dated on 2018-09-05: Sangamo Says Will Host Conference Call, Webcast To Discuss SB-913 At 9 a.m. EDT Wed.

Financial news for SGMO dated on 2018-09-05: UPDATE: Sangamo Highlights 'SB-913 has been generally well-tolerated with no treatment related serious adverse events in patients up to 32 weeks'

Financial news for SGMO dated on 2018-09-05: UPDATE: Sangamo Highlights 'Total urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks'

Financial news for SGMO dated on 2018-09-05: Sangamo Therapeutics Highlights Presentation At Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Evaluating SB-913 Which Showed Early Data From Cohorts 1, 2, Enrollment Of Cohort 3 Recently Completed

Financial news for SGMO dated on 2018-09-04: Sangamo Therapeutics Option Alert: Sep 21 \$20 Calls at the Ask: 600 @ \$1.7 vs 8905 OI; Ref=\$18.35

Financial news for SGMO dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for SGMO dated on 2018-08-10: 77 Biggest Movers From Yesterday

Financial news for SGMO dated on 2018-08-09: 68 Stocks Moving In Thursday's Mid-Day Session

Financial news for SGMO dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for SGMO dated on 2018-08-08: Sangamo Therapeutics Reports Prelim.

Data From Phase 1/2 Alta Study Evaluating SB-525: 'has been generally well tolerated'

Financial news for SGM0 dated on 2018-08-08: Sangamo BioSciences Q2 EPS \$(0.17) Misses \$(0.15) Estimate, Sales \$21.416M Miss \$21.43M Estimate; Expects To Have Cash, Cash Equivalents, Marketable Securities, Interest Receivable Of At Least \$380M At End Of 2018

Financial news for SGM0 dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for SGM0 dated on 2018-07-23: Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318

Financial news for SGM0 dated on 2018-07-23: Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318

Financial news for SGM0 dated on 2018-07-23: A Peek Into The Markets: US Stock Futures Down; Alphabet Earnings In Focus

Financial news for SGM0 dated on 2018-07-23: Sangamo Therapeutics to Acquire TxCell for EUR2.58/Share in Cash

Financial news for SGM0 dated on 2018-06-21: 50 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2018-06-20: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for SGM0 dated on 2018-06-20: Benzinga's Top Upgrades, Downgrades For June 20, 2018

Financial news for SGM0 dated on 2018-06-20: Bank of America Initiates Coverage On Sangamo Therapeutics with Buy Rating, Announces \$24 Price Target

Financial news for SGM0 dated on 2018-06-11: Adam Feuerstein Tweets: BREAKING --> A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies <https://www.statnews.com/2018/06/11/crispr-hurdle-edited-cells-might-cause-cancer/> ... via @sxbegle \$CRSP \$EDIT \$NTLA \$SGMO

Financial news for SGM0 dated on 2018-06-04: Sangamo Announces UK Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments

Financial news for SGM0 dated on 2018-05-16: Bioverativ, Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease

Financial news for SGM0 dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for SGM0 dated on 2018-05-08: Sangamo BioSciences Q1 EPS \$(0.23) Does Not Compare To \$0.48 Estimate, Sales \$12.63M Does Not Compare To \$53.09M Estimate

Financial news for SGM0 dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for SGM0 dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for SGM0 dated on 2018-04-27: Sangamo Announces \$8M CIRM Grant For ST-400

Financial news for SGM0 dated on 2018-04-26: Sangamo Therapeutics Prices 12.31M Share Public Offering of Common Stock @\$16.25/Share

Financial news for SGM0 dated on 2018-04-25: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGM0 dated on 2018-04-25: Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen

Financial news for SGM0 dated on 2018-04-25: 15 Stocks To Watch For April 25, 2018

Financial news for SGM0 dated on 2018-04-24: Sangamo Therapeutics Shares Down 7.0% After Hours Following Announcement Of \$200M Common Stock Offering

Financial news for SGM0 dated on 2018-04-24: Sangamo Therapeutics Announces \$200M Public Offering

Financial news for SGM0 dated on 2018-04-23: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2018-04-17: UPDATE: Sangamo Says Investigation Did Not Reveal Evidence Co.'s Network, Other IT Systems Were Otherwise Compromised

Financial news for SGM0 dated on 2018-04-17: UPDATE: Sangamo Says Upon Learning Of Data Security Incident, External Network Security Experts Were Promptly Engaged

Financial news for SGM0 dated on 2018-04-17: Sangamo Therapeutics 8-K Shows Data Security Incident Which Compromised A Senior Execs Email Account

Financial news for SGM0 dated on 2018-04-11: Sangamo Option Alert: Apr 20 \$21 Calls at the Bid: 879 @ \$0.451 vs 423 OI; Earnings 5/9 After Close [est] Ref=\$19.35

Financial news for SGM0 dated on 2018-04-04: UPDATE: Sangamo Says 'Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial'

Financial news for SGM0 dated on 2018-04-04: Sangamo Therapeutics Reports Publication In Molecular Therapy Preclinical Study Data From MPS II In Vivo Genome Editing Program

Financial news for SGM0 dated on 2018-03-28: 38 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2018-02-28: Sangamo Reports U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B

Financial news for SGM0 dated on 2018-02-23: 56 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2018-02-22: Mid-Afternoon Market Update: Crude Oil Up Over 1.5%; Whiting Petroleum Shares Climb After Strong Q4 Results

Financial news for SGM0 dated on 2018-02-22: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for SGM0 dated on 2018-02-22: Mid-Day Market Update: Dow Rises Over 1%; Applied Optoelectronics Shares Plummet

Financial news for SGM0 dated on 2018-02-22: Sangamo Therapeutics Shares Up 19.8% After Deal With Gilead For Oncology-Focused Cell Therapies, Better-Than-Expected Q4 Results

Financial news for SGM0 dated on 2018-02-22: Mid-Morning Market Update: Markets Open Higher; PPL Profit Tops Expectations

Financial news for SGM0 dated on 2018-02-22: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2018-02-22: Sangamo Therapeutics Reports Q4 EPS \$(0.15) vs \$(0.18) est., Sales \$13.1M vs \$11.4M Est.

Financial news for SGM0 dated on 2018-02-22: Gilead's Kite, Sangamo Therapeutics Partner To Develop Generation Engineered Cell Therapies For Cancer Treatment, Sangamo To Receive Upfront Payment Of \$150M With \$3.01B In Potential Milestone Payments

Financial news for SGM0 dated on 2018-02-07: Sangamo Therapeutics Announces an \$11 Million Grant Fro the National Institute of Health for Study of Gene-Edited T Cells for Viral Eradication of HIV

Financial news for SGM0 dated on 2018-01-24: Sangamo Option Alert: Feb 16 \$20 Puts Sweep (29) at the Ask: 2915 @ \$2.101 vs 468 OI; Earnings 2/27 Before Open [est] Ref=\$19.75

Financial news for SGM0 dated on 2018-01-24: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGM0 dated on 2018-01-23: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for SGM0 dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for SGM0 dated on 2018-01-22: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for SGM0 dated on 2018-01-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2018-01-03: Sangamo to Receive a \$12M Upfront Payment From Pfizer For a Collaboration On Zinc Finger Protein Gene Therapy for ALS

Financial news for SGMO dated on 2018-01-02: Shares Of Gene Therapy Development Stocks Showing Strength Tuesday: CRSP +7.2%, EDIT +10.22%, SGMO +7.01%, BOLD +4.8%

Financial news for SGMO dated on 2017-12-27: 4 Biotech Stocks Ready To Crush The Market In 2018

Financial news for SGMO dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for SGMO dated on 2017-12-08: Sangamo Option Alert: Feb 16 \$20 Calls Sweep (3) at the Bid: 1541 @ \$1.554 vs 99 OI; Ref=\$17.1 Signals

Financial news for SGMO dated on 2017-12-07: Sangamo Therapeutics Reports EMA Recommended Orphan Medicinal Product Designation For Investigational Genome Editing Treatments for MPS I, II

Financial news for SGMO dated on 2017-12-04: Sangamo Therapeutics Make New 52-week High \$18.40, Now Up 4.23% At \$17.25

Financial news for SGMO dated on 2017-12-04: 4 Biotech Stocks To Better Your Financial Health This Winter

Financial news for SGMO dated on 2017-12-01: 38 Biggest Movers From Yesterday

Financial news for SGMO dated on 2017-11-22: Benzinga's Top Upgrades, Downgrades For November 22, 2017

Financial news for SGMO dated on 2017-11-22: Barclays Initiates Coverage On Sangamo Therapeutics with Overweight Rating, Announces \$20.00 Price Target

Financial news for SGMO dated on 2017-11-16: 40 Biggest Movers From Yesterday

Financial news for SGMO dated on 2017-11-15: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for SGMO dated on 2017-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2017

Financial news for SGMO dated on 2017-11-15: PiperJaffray Upgrades Sangamo Therapeutics to Overweight

Financial news for SGMO dated on 2017-11-15: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGMO dated on 2017-11-15: Sangamo Announces First Patient Treated in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Financial news for SGMO dated on 2017-11-13: 44 Biggest Movers From Friday

Financial news for SGMO dated on 2017-11-10: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for SGMO dated on 2017-11-09: Sangamo Announces Strategic Investment In Manufacturing

Financial news for SGMO dated on 2017-11-09: Sangamo Therapeutics Reports Q3 EPS \$(0.15) vs \$(0.19) Est., Sales \$11.812M

Financial news for SGMO dated on 2017-11-08: Barclays: Editas Medicine On Track To File New Drug App Next Year

Financial news for SGMO dated on 2017-10-18: Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More

Financial news for SGMO dated on 2017-10-06: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for SGMO dated on 2017-10-02: Sangamo, Bioverativ Report FDA Acceptance Of IND Application For ST-400

Financial news for SGMO dated on 2017-09-21: Genome Editing Stocks Strong This Morning, Not Seeing Any News: Intellia Therapeutics Shares Up 9%, Editas Up 4.5%, Sangamo Up 0.6%, Collectis Up 0.2%; 1 Outlier Is Crispr Therapeutics, Down 1% For Session

Financial news for SGMO dated on 2017-09-19: Secondary Offering Lockup Expirations Today From Determine, Sangamo Therapeutics, Avexis, and Valeritas

Financial news for SGM0 dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2017-08-25: Sangamo Therapeutics, Pfizer Report First Patient Received Treatment In Phase 1/2 Trial Evaluating SB-525

Financial news for SGM0 dated on 2017-08-11: Mid-Day Market Update: Aegean Marine Rises After Q2 Results; Black Box Shares Plunge

Financial news for SGM0 dated on 2017-08-09: Sangamo Therapeutics Reports Q2 EPS \$(0.17) vs \$(0.19) Est., Sales \$8.3M vs \$6M Est.

Financial news for SGM0 dated on 2017-07-14: 15 Biggest Mid-Day Gainers For Friday

Financial news for SGM0 dated on 2017-07-14: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for SGM0 dated on 2017-07-13: Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913

Financial news for SGM0 dated on 2017-06-25: Benzinga's Bulls & Bears For The Past Week: Netflix, AMD, Colgate And More

Financial news for SGM0 dated on 2017-06-23: 6 Biotech Stocks Jefferies Says Are Undervalued

Financial news for SGM0 dated on 2017-06-22: Mid-Afternoon Market Update: Steelcase Tumbles Following Disappointing Earnings Report; Staples Shares Surge

Financial news for SGM0 dated on 2017-06-22: Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet

Financial news for SGM0 dated on 2017-06-22: Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings

Financial news for SGM0 dated on 2017-06-21: 12 Biggest Mid-Day Losers For Wednesday

Financial news for SGM0 dated on 2017-06-21: Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations

Financial news for SGM0 dated on 2017-06-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGM0 dated on 2017-06-21: Sangamo Therapeutics Prices 10M Shares At \$7.25/Share

Financial news for SGM0 dated on 2017-06-20: Sangamo Therapeutics Reports Offering Of Common Shares, Amount Not Disclosed

Financial news for SGM0 dated on 2017-06-07: Sangamo Therapeutics, Pfizer Report SB-525 Received Orphan Medicinal Production Designation from EMA

Financial news for SGM0 dated on 2017-05-23: Benzinga's Option Alert Recap From May 23

Financial news for SGM0 dated on 2017-05-23: Option Alert: Sangamo Jun 7.0 Calls Sweep: 865 @ ASK \$0.998: 2055 traded vs 1407 OI: Earnings 8/2 After Close (est) \$7.65 Ref

Financial news for SGM0 dated on 2017-05-16: Benzinga's Option Alert Recap From May 16

Financial news for SGM0 dated on 2017-05-16: Option Alert: Sangamo May 8.0 Puts Sweep: 500 @ ASK \$0.40: 1043 traded vs 600 OI: Earnings 8/2 After Close (est) \$7.89 Re

Financial news for SGM0 dated on 2017-05-16: Sangamo Gets Fast Track Designation for SB-525

Financial news for SGM0 dated on 2017-05-12: Mid-Afternoon Market Update: Inpixon Drops Following Q1 Results; Technical Communications Shares Spike Higher

Financial news for SGM0 dated on 2017-05-12: 15 Biggest Mid-Day Gainers For Friday

Financial news for SGM0 dated on 2017-05-11: Mid-Afternoon Market Update: Crude Oil Up 1.25%; Straight Path Shares Plunge

Financial news for SGM0 dated on 2017-05-11: 12 Biggest Mid-Day Gainers For Thursday

Financial news for SGM0 dated on 2017-05-11: Mid-Day Market Update: Snap Tumbles After Q1 Report; Sangamo Shares Surge

Financial news for SGM0 dated on 2017-05-11: Mid-Morning Market Update: Markets Open Lower; Macy's Profit Misses Expectations

Financial news for SGM0 dated on 2017-05-11: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2017-05-11: Sangamo+40% Premarket @\$6.10 Following Wednesday Earnings Report, Co Announced Strategic Collaboration with Pfizer for Hemophilia A Phase 1/2 Therapy Program

Financial news for SGM0 dated on 2017-05-10: Sangamo Shares Resume, Now Up 42%

Financial news for SGM0 dated on 2017-05-10: Sangamo Shares to Resume Trade at 4:30 p.m. EDT

Financial news for SGM0 dated on 2017-05-10: Sangamo Reports Strategic Collaboration with Pfizer for Hemophilia A Phase 1/2 Therapy Program

Financial news for SGM0 dated on 2017-05-10: Sangamo Therapeutics Reports Q1 EPS \$(0.23) vs \$(0.26) Est., Sales \$3.4M vs \$4.3M Est.

Financial news for SGM0 dated on 2017-05-10: Sangamo Shares Halted News Pending

Financial news for SGM0 dated on 2017-05-04: Sangamo Therapeutics Reports Special Regulatory Designations from the FDA For SB-913, SB-525, & SB-FIX

Financial news for SGM0 dated on 2017-03-30: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2017-03-29: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for SGM0 dated on 2017-03-29: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGM0 dated on 2017-03-29: Sangamo Therapeutics Reports Presentation of New Data Showing 'significant reduction of tau mRNA, tau protein expression using ZFP-TF-mediated gene regulation technology'

Financial news for SGM0 dated on 2017-03-01: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913

Financial news for SGM0 dated on 2017-02-28: Sangamo Therapeutics Reports Q4 EPS \$(0.14) vs. \$(0.25) Est., Sales \$8.92M

Financial news for SGM0 dated on 2017-02-27: Sangamo Therapeutics Reports CFO H. Ward Wolff To Retire, Kathy Yi Named Successor

Financial news for SGM0 dated on 2017-02-27: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2017-02-27: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318

Financial news for SGM0 dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for SGM0 dated on 2017-02-02: Hemophilia Fighter Bioverativ Launches On NASDAQ

Financial news for SGM0 dated on 2017-01-19: Mid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher

Financial news for SGM0 dated on 2017-01-19: Mid-Day Market Update: Oclaro Surges Following Strong Q2 Outlook; Zynerva Pharmaceuticals Shares Decline

Financial news for SGM0 dated on 2017-01-17: Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates

Financial news for SGM0 dated on 2017-01-13: 12 Biggest Mid-Day Gainers For Friday

Financial news for SGM0 dated on 2017-01-13: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for SGM0 dated on 2017-01-11: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for SGM0 dated on 2017-01-11: 22 Stocks Moving In Wednesday's Pre-

Market Session

Financial news for SGM0 dated on 2017-01-11: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318

Financial news for SGM0 dated on 2017-01-05: 18 Biggest Mid-Day Losers For Thursday

Financial news for SGM0 dated on 2017-01-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2017-01-05: Sangamo BioSciences Gets FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Financial news for SGM0 dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for SGM0 dated on 2016-12-20: Mid-Afternoon Market Update: Worthington Drops On Earnings Miss; Fred's Shares Spike Higher

Financial news for SGM0 dated on 2016-12-09: Mid-Afternoon Market Update: Restoration Hardware Tumbles On Weak Guidance; Stillwater Mining Shares Spike Higher

Financial news for SGM0 dated on 2016-12-09: Mid-Morning Market Update: Markets Open Higher; Finisar Beats Q2 Estimates

Financial news for SGM0 dated on 2016-12-08: Mid-Morning Market Update: Markets Edge Lower; Ciena Profit Misses Estimates

Financial news for SGM0 dated on 2016-12-05: Sangamo BioSciences Presents Hemophilia A Program Data at ASH 2016

Financial news for SGM0 dated on 2016-11-01: Sangamo BioSciences Restructuring Creates A Pipeline Gap, Merits 87% PT Decrease

Financial news for SGM0 dated on 2016-11-01: Stocks Hitting 52-Week Lows

Financial news for SGM0 dated on 2016-11-01: 7 Biggest Price Target Changes For Tuesday

Financial news for SGM0 dated on 2016-11-01: Benzinga's Top Downgrades

Financial news for SGM0 dated on 2016-11-01: Wedbush Downgrades Sangamo BioSciences, Inc. - Common Stock to Neutral, Lowers to \$4.00

Financial news for SGM0 dated on 2016-10-26: Sangamo BioSciences Reports Q3 Loss/Share \$0.27 vs Est Loss/Share Of \$0.25, Rev \$2.8M

Financial news for SGM0 dated on 2016-10-19: Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge

Financial news for SGM0 dated on 2016-10-19: 15 Biggest Mid-Day Losers For Wednesday

Financial news for SGM0 dated on 2016-10-19: Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration

Financial news for SGM0 dated on 2016-10-19: PiperJaffray Downgrades Sangamo BioSciences, Inc. - Common Stock to Neutral

Financial news for SGM0 dated on 2016-10-19: 16 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGM0 dated on 2016-10-12: Mid-Afternoon Market Update: Crude Oil Down Over 1%; VOXX Shares Spike Higher

Financial news for SGM0 dated on 2016-10-11: Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure

Financial news for SGM0 dated on 2016-09-06: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for SGM0 dated on 2016-09-06: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for SGM0 dated on 2016-09-06: Sangamo Biosciences Gets orphan Drug Designation For SB-FIX

Financial news for SGM0 dated on 2016-09-06: Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX

Financial news for SGM0 dated on 2016-08-04: 20 Biggest Mid-Day Losers For Thursday

Financial news for SGM0 dated on 2016-08-04: Mid-Day Market Update: Crude Oil Rises Over 2%; Sangamo Biosciences Drops Following Weak Q2 Results

Financial news for SGM0 dated on 2016-08-04: Mid-Morning Market Update: Markets Edge Lower; Viacom Tops Q3 Expectations

Financial news for SGM0 dated on 2016-08-04: Benzinga's Top Downgrades

Financial news for SGM0 dated on 2016-08-04: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGM0 dated on 2016-08-04: Janney Capital Downgrades Sangamo BioSciences to Neutral

Financial news for SGM0 dated on 2016-08-03: After-Hours Losers Aug. 3, '16: TDOC Down 24%, SGM0 18.4%, BSQR 15.9%, TEGP 14.7%, FRSH 14.4%, BBRG 13.9%, INOV 13.9%, ADAP 12.9%

Financial news for SGM0 dated on 2016-08-03: Sangamo BioSciences Reports Q2 Rev. \$3.7M vs. Est. \$5.3M

Financial news for SGM0 dated on 2016-08-03: Sangamo Biosciences Reports Q2 EPS \$(0.38) vs. Est. \$(0.24)

Financial news for SGM0 dated on 2016-07-26: Sangamo BioSciences Reveals New Gene Therapy Clinical Development Program For Hemophilia A Treatment

Financial news for SGM0 dated on 2016-07-26: UPDATE: Sangamo Says Will Update Guidance for In Vivo Genome Editing Approach for Hemophilia A, Other Programs During Q2 Earnings Conference Call

Financial news for SGM0 dated on 2016-07-26: UPDATE: Sangamo Sees Filing Investigational NDA for New Factor VIII Gene Therapy Approach in '16

Financial news for SGM0 dated on 2016-07-26: Sangamo Biosciences Reports New Gene Therapy Clinical Developmen Program for Treatment of Hemophilia A

Financial news for SGM0 dated on 2016-06-20: Sangamo BioSciences Gets FDA Approval For IND For ZFN-Mediated Genome Editing Treatment Of MPS II

Financial news for SGM0 dated on 2016-06-20: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II

Financial news for SGM0 dated on 2016-06-01: Sangamo Biosciences CEO Edward Lanphier To Retire, Names Sandy Macrae Successor

Financial news for SGM0 dated on 2016-06-01: Sangamo Biosciences Announces CEO to Retire

Financial news for SGM0 dated on 2016-05-02: Sangamo Reaffirms FY16 Sales \$20M-\$25M vs \$22.8M Est.

Financial news for SGM0 dated on 2016-05-02: Sangamo Biosciences Reports Q1 EPS \$(0.23) vs \$(0.24) Est., Sales \$3.9M vs \$5.5M Est.

Financial news for SGM0 dated on 2016-04-18: Sangamo BioSciences To Present On ZFP Therapeutic Programs & Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy

Financial news for SGM0 dated on 2016-02-09: Sangamo Sees FY16 Sales \$20M-\$25M vs \$34M Est.

Financial news for SGM0 dated on 2016-02-09: Sangamo BioSciences Reports Q4 EPS \$(0.20) vs \$(0.21) Est., Sales \$9.1M vs \$9.9M Est.

Financial news for SGM0 dated on 2016-02-08: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for SGM0 dated on 2016-02-08: Sangamo BioSciences Reports FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Financial news for SGM0 dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for SGM0 dated on 2015-12-18: Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

Financial news for SGM0 dated on 2015-12-17: Janney Capital Initiates Coverage on Sangamo BioSciences at Buy

Financial news for SGM0 dated on 2015-12-11: Sangamo BioSciences Shows Phase 2 Clinical Data From Two SB-728-T HIV Studies

Financial news for SGM0 dated on 2015-12-08: Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

Financial news for SGM0 dated on 2015-12-07: Sangamo BioSciences Shares Up ~4% On The Day With ASH Conf. Data On ZFP Therapeutic Programs For Hemophilia & Hemoglobinopathies Out

Financial news for SGM0 dated on 2015-12-04: Wells Fargo Initiates Coverage on Sangamo BioSciences at Outperform

Financial news for SGM0 dated on 2015-12-02: Wedbush Reiterates Outperform Rating, \$30 Price Target on Sangamo as Co. 'Cleared to Initiate In-Vivo Human Testing of its ZFN Based Protein Replacement Platform'

Financial news for SGM0 dated on 2015-12-01: Mid-Afternoon Market Update: Dow Climbs Over 100 Points; HF Financial Shares Rise On Merger News

Financial news for SGM0 dated on 2015-12-01: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B

Financial news for SGM0 dated on 2015-10-28: Sangamo Biosciences Reports Q3 Loss of \$0.13/Share vs Loss of \$0.24/Share Est., Sales \$8.6M vs \$13M Est.

Financial news for SGM0 dated on 2015-10-23: Sangamo Shares Up 13+% Following Earlier New Buy Rating, \$14 Price Target from Jefferies

Financial news for SGM0 dated on 2015-09-30: Sangamo BioSciences Announces Presentation At The 2015 Stem Cell Meeting On The Mesa - 2:30pm PT on Wednesday, October 7, 2015

Financial news for SGM0 dated on 2015-09-21: Sangamo BioSciences Reports Updated Clinical Data from ZFP Therapeutic(r) Program for HIV/AIDS at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy

Financial news for SGM0 dated on 2015-09-10: UPDATE: Sangamo Biosciences Shares +25% Following Earlier Announcement of Unanimous Recombinant DNA Advisory Committee Approval of ZFP Therapeutic Phase 1 Study Protocol for First in Vivo Genome Editing Application

Financial news for SGM0 dated on 2015-09-10: Sangamo Biosciences Spiking Higher

Financial news for SGM0 dated on 2015-09-10: Sangamo Report Unanimous Recombinant DNA Advisory Committee (RAC) Approval Of ZFP Therapeutic Phase 1 Study Protocol For First In Vivo Genome Editing Application

Financial news for SGM0 dated on 2015-09-03: Mid-Morning Market Update: Markets Gain; Campbell Soup Earnings Top Estimates

Financial news for SGM0 dated on 2015-09-02: Sangamo, Shire Restructure Partnership to Accelerate Development of ZFP Therapeutics(r) for the Treatment of Hemophilia and Huntington's Disease

Financial news for SGM0 dated on 2015-08-05: Sangamo Reports Q2 Loss of \$0.17/Share vs Loss of \$0.13/Share Est., Sales \$8.4M vs \$15M Est.

Financial news for SGM0 dated on 2015-06-03: Wednesday's After-Hours Movers: Five Below, FireEye And More

Financial news for SGM0 dated on 2015-05-18: Sangamo Reports Presentation of New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storage Disorders at ASGCT

Financial news for SGM0 dated on 2015-05-14: Sangamo BioSciences Provides Clinical Update On SB-728-T Program

Financial news for SGM0 dated on 2015-05-13: Sangamo BioSciences Announces Joint Steering Committee Decision To Consolidate ZFP Therapeutic(r) Strategy For Hemoglobinopathies

Financial news for SGM0 dated on 2015-05-13: Sangamo Biosciences Reports Joint

Steering Committee Decision to Consolidate ZFP Therapeutic Strategy for Hemoglobinopathies

Financial news for SGMO dated on 2015-04-30: Biogen Or Bluebird: Which Will Lead In SCD?

Financial news for SGMO dated on 2015-04-27: Gene Therapy Stocks Take Beating On Bad News For Celladon

Financial news for SGMO dated on 2015-04-22: BMO Capital Initiates Coverage on Sangamo BioSciences at Outperform, Announces \$19.00 PT

Financial news for SGMO dated on 2015-04-22: Sangamo Biosciences Reports Q1 Loss of \$0.08/Share vs Loss of \$0.13/Share Est., Sales \$13.49M vs \$12.1M Est.

Financial news for SGMO dated on 2015-04-13: Jefferies: 10 Buyout Targets To Own During The M&A Boom

Financial news for SGMO dated on 2015-03-03: Sangamo BioSciences Shares Move Higher; May be Attributed to Blog Post via @blinkX90

Financial news for SGMO dated on 2015-02-26: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for SGMO dated on 2015-02-26: Sangamo BioSciences Reports Positive Clinical Data from Trial of ZFP Therapeutic Designed to Provide Functional Control of HIV

Financial news for SGMO dated on 2015-02-26: Sangamo BioSciences Announces FDA Acceptance of IND Application for New HIV/AIDS Clinical Trial Using ZFN-Modification of Hematopoietic Stem Cells

Financial news for SGMO dated on 2015-02-11: Mid-Day Market Update: Interxion Surges On Merger Agreement With TelecityGroup; Marketo Shares Slide

Financial news for SGMO dated on 2015-02-10: Sangamo Reports Q4 Loss of \$0.06/Share, Sales \$15M; Sees FY15 Sales \$60M-\$70M

Financial news for SGMO dated on 2015-02-04: Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of ZFP Therapeutic for Beta-Thalassemia

Financial news for SGMO dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for SGMO dated on 2014-12-29: Sangamo Biosciences Shares Spike Higher

Financial news for SGMO dated on 2014-12-17: Is Sangamo The Next Biotech Stock To Break Out?

Financial news for SGMO dated on 2014-12-09: Sangamo Shares Spike Higher

Financial news for SGMO dated on 2014-11-19: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms

Financial news for SGMO dated on 2014-10-22: Sangamo BioSciences, Inc. Reports Q3 EPS of \$(0.11) vs \$(0.14) Est; Revenue of \$12.40M vs \$8.27M Est

Financial news for SGMO dated on 2014-10-16: Sangamo BioSciences ZFP Therapeutic Program In HIV/AIDS Featured At Three Major Scientific Conferences In October 2014

Financial news for SGMO dated on 2014-09-23: Dow Finishes Down 100+ Points For Second Consecutive Day

Financial news for SGMO dated on 2014-09-23: Dow Down 0.6%; CarMax Shares Fall After Q2 Results

Financial news for SGMO dated on 2014-09-23: Shares of Sangamo Ticking Higher as CNBC Mentioning Early-Morning New Buy Rating and \$22 Price Target from Jefferies

Financial news for SGMO dated on 2014-09-23: Ascena Retail Drops On Downbeat Earnings; CF Industries Shares Gain

Financial news for SGMO dated on 2014-09-23: Markets Mixed; Carnival Profit Tops Street View

Financial news for SGMO dated on 2014-09-23: Morning Market Movers

Financial news for SGMO dated on 2014-09-23: Jefferies Initiates Coverage on Sangamo

BioSciences, Inc. at Buy, Announces \$22.00 PT

Financial news for SGMO dated on 2014-09-10: Sangamo Biosciences, Inc. Is Preparing To Drop Big

Financial news for SGMO dated on 2014-09-10: Sangamo Reports Target Date for First IND for In Vivo ZFN Genome-Editing Platform, Sees Submission in Q2'15, Sees IND for Hemophilia by Year End '15

Financial news for SGMO dated on 2014-09-09: J.P. Morgan Sees Sangamo Biosciences, Inc. As Attractive Investment Opportunity

Financial news for SGMO dated on 2014-08-01: UPDATE: J.P. Morgan Initiates Coverage On Sangamo Biosciences On Potentially Disruptive Future

Financial news for SGMO dated on 2014-08-01: Benzinga's Top Initiations

Financial news for SGMO dated on 2014-08-01: JP Morgan Initiates Sangamo BioSciences With Overweight

Financial news for SGMO dated on 2014-08-01: JP Morgan Initiates Coverage on Sangamo BioSciences, Inc. at Overweight, Announces \$22.00 PT

Financial news for SGMO dated on 2014-07-23: Sangamo BioSciences, Inc. Reports Q2 EPS of \$(0.10) vs \$(0.14) Est; Revenue of \$10.40M vs \$7.84M Est

Financial news for SGMO dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for SGMO dated on 2014-05-30: Sangamo Announces Co., City of Hope Win Strategic Partnership from California Institute for Regenerative Medicine to Support Clinical Trial of Stem-Cell Based ZFP Therapeutic for HIV/AIDS

Financial news for SGMO dated on 2014-05-28: Sangamo Publishes Preclinical Data Showing Gene Correction in SCID-X1 Human Hematopoietic Stem Cells

Financial news for SGMO dated on 2014-05-27: Sangamo BioSciences Clinical Update on SB-728-T Program and Progress in Other ZFP Applications at ASGCT

Financial news for SGMO dated on 2014-05-14: Sangamo BioSciences to Present Data on ZFP Therapeutic Applications and Developments at ASGCT

Financial news for SGMO dated on 2014-03-21: Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher

Financial news for SGMO dated on 2014-03-20: Sangamo BioSciences Prices 4.44M Share Offering at \$22.50/Share

Financial news for SGMO dated on 2014-03-19: Sangamo BioSciences Announces \$100M Public Offering of Common Stock

Financial news for SGMO dated on 2014-03-06: Sangamo Biosciences CEO Lanphier: 'One of the Tools we Use is Whole Genome Sequencing'

Financial news for SGMO dated on 2014-03-06: Sangamo Biosciences CEO Lanphier: 'We are in a Strong Financial Position'

Financial news for SGMO dated on 2014-03-06: Sangamo Biosciences CEO Lanphier: 'We are Not Trying to Treat the Disease, We are Trying to Change the DNA so we can Cure It'

Financial news for SGMO dated on 2014-03-06: Jim Cramer Interviews CEO Edward O. Lanphieri of Sangamo Biosciences on Mad Money

Financial news for SGMO dated on 2014-03-06: Mid-Afternoon Market Update: Markets Turn Up From the Lows, Fuel Cell Companies Show Weakness

Financial news for SGMO dated on 2014-03-06: Mid-Day Market Update: Costco Shares Decline After Weak Quarterly Results; Stage Stores Spikes Higher

Financial news for SGMO dated on 2014-03-06: Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI

Financial news for SGMO dated on 2014-03-06: Benzinga's Volume Movers

Financial news for SGMO dated on 2014-03-06: Mid-Morning Market Update: Markets Open Higher; Staples Plans To Close 225 Stores

Financial news for SGMO dated on 2014-03-06: Benzinga's Top #PreMarket Gainers

Financial news for SGMO dated on 2014-03-05: Sangamo Shares Spike Higher as Co Announces First-In-Man Study Of Genome Editing Using Sangamo's ZFN Technology Published In New England Journal Of Medicine

Financial news for SGMO dated on 2014-03-03: Option Alert; Sangamo July \$25 Call; Aug \$47 Call; 1m673 Contract Trade Between Bid and Ask @\$2.35; Currently \$18.09

Financial news for SGMO dated on 2014-02-26: Sangamo Biosciences Spikes Lower

Financial news for SGMO dated on 2014-02-25: Sangamo Files Automatic Mixed Securities Shelf

Financial news for SGMO dated on 2014-02-11: Sangamo BioSciences, Inc. Sees FY2014 Sales \$45.0M-50.0M vs \$35.50M Est

Financial news for SGMO dated on 2014-02-11: Sangamo BioSciences, Inc. Reports Q4 EPS of \$(0.13) vs \$(0.10) Est; Revenue of \$6.87M vs \$5.69M Est

Financial news for SGMO dated on 2014-01-29: Option Alert: Sangamo BioSciences Jan 2015 \$15 Call; 30,000 Contract Trade Between Bid and Ask @\$6.00; Currently \$18.81

Financial news for SGMO dated on 2014-01-17: Option Alert: Sangamo BioSciences Jan 2015 \$25 Call; 2,500 Contract Trade Between Bid and Ask @\$2.85; Currently \$19.66

Financial news for SGMO dated on 2014-01-16: Sangamo Says has Strong Cash Position

Financial news for SGMO dated on 2014-01-16: Sangamo Biosciences Exec Presentation at JP Morgan Healthcare Conf. Just Getting Underway

Financial news for SGMO dated on 2014-01-16: Sangamo BioSciences Spikes Hgher

Financial news for SGMO dated on 2014-01-09: Market Wrap For January 9: All Eyes on Tomorrow's Job Report

Financial news for SGMO dated on 2014-01-09: Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings

Financial news for SGMO dated on 2014-01-09: Benzinga's Volume Movers

Financial news for SGMO dated on 2014-01-09: Stocks Hitting 52-Week Highs

Financial news for SGMO dated on 2014-01-09: Morning Market Movers

Financial news for SGMO dated on 2014-01-09: Benzinga's Top #PreMarket Gainers

Financial news for SGMO dated on 2014-01-09: Sangamo BioSciences, Biogen Partnership to Develop Novel Therapies for Sickle Cell Disease, Beta-Thalassemia

Financial news for SGMO dated on 2013-12-10: Sangamo Presents Data from In Vivo Protein Replacement Platform at ASH

Financial news for SGMO dated on 2013-12-09: Stocks to Watch for December 09, 2013

Financial news for SGMO dated on 2013-12-09: Sangamo Presents Data From ZFP Therapeutic Program for Treatment Of Sickle Cell Disease And Beta-Thalassemia at ASH

Financial news for SGMO dated on 2013-11-15: Sangamo Biosciences Reports Presentation of Clinical Data from Alzheimer's Program

Financial news for SGMO dated on 2013-11-15: Sangamo BioSciences Presentats Positive Data from Alzheimer's Disease Treatment

Financial news for SGMO dated on 2013-11-04: US Stock Futures Up Ahead Of Factory Orders Data

Financial news for SGMO dated on 2013-11-04: Sangamo Presents Positive Clinical Data from SB-728-T HIV Study

Financial news for SGMO dated on 2013-11-04: Sangamo BioSciences Reports Study Results from SB-728-T for HIV Showed Reduction

Financial news for SGMO dated on 2013-10-28: Sangamo BioSciences Presents Promising HIV Study Data

Financial news for SGMO dated on 2013-10-23: Sangamo BioSciences, Inc. Reports Q3 EPS of \$(0.11), Inline; Revenue of \$5.71M vs \$5.52M Est

Financial news for SGMO dated on 2013-09-23: Sangamo BioSciences Closes Offering of

6.1M Shares at \$10.58/Share

Financial news for SGMO dated on 2013-09-19: Streetsweeper Report: 'Sangamo: A fiery biotech with a product poised to go down in flames?''

Financial news for SGMO dated on 2013-09-19: TheStreetSweeper releases its investigative report on Sangamo Biosciences

Financial news for SGMO dated on 2013-09-18: Sangamo Biosciences Prices Offering of 6.1M Share at \$10.58/Share

Financial news for SGMO dated on 2013-09-18: Benzinga's Top Pre-Market Losers

Financial news for SGMO dated on 2013-09-17: Sangamo Biosciences Reports Offering of Common Stock

Financial news for SGMO dated on 2013-09-13: Benzinga's Top Pre-Market Gainers

Financial news for SGMO dated on 2013-09-12: Sangamo BioSciences Announces Data from Trial of SB-728-T Shows Sustained Cut of Viral Load At or Below Detect Limit

Financial news for SGMO dated on 2013-08-26: Sangamo to Buy Ceregene

Financial news for SGMO dated on 2013-08-14: Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology

Financial news for SGMO dated on 2013-07-24: Sangamo BioSciences, Inc. Reports Q2 EPS of \$(0.10) vs \$(0.13) Est; Revenue of \$6.93M vs \$4.77M Est

Financial news for SGMO dated on 2013-07-17: Technology Made By Sangamo Biosciences Used In Gene Splicing to Find Cure For Down Syndrome Showing Success - Nature

Financial news for SGMO dated on 2013-06-17: Cowen & Company Initiates Coverage on Sangamo BioSciences, Inc. at Outperform

Financial news for SGMO dated on 2013-05-24: Sangamo BioSciences Receives \$6.4M Strategic Partnership Award from CIRM

Financial news for SGMO dated on 2013-05-15: UPDATE: Sangamo Highlights Encouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials

Financial news for SGMO dated on 2013-05-08: Sangamo BioSciences, Inc. Reports Q1 EPS of \$(0.13) vs \$(0.16) Est; Revenue of \$4.62M vs \$3.79M Est

Financial news for SGMO dated on 2013-04-12: Stocks to Watch for April 12, 2013

Financial news for SGMO dated on 2013-04-03: Sangamo, Alnylam Shares Spike Higher on Positive Jim Cramer/Mad Money Comments

Financial news for SGMO dated on 2013-03-28: JMP Securities Initiates Coverage on Sangamo BioSciences, Inc. at Market Outperform, Announces \$16.00 PT

Financial news for SGMO dated on 2013-03-15: Report of 14 Adults 'Cured' of HIV -NewScientist

Financial news for SGMO dated on 2013-03-07: UPDATE: Wedbush Raises PT to \$13 on Sangamo BioSciences on HIV Progress, Time Value

Financial news for SGMO dated on 2013-03-07: Wedbush Maintains Outperform on Sangamo BioSciences, Inc., Raises PT to \$13.00

Financial news for SGMO dated on 2013-03-06: Sangamo Presenting New Data at CROI 2013 Which Demonstrates Persistent Immune System Improvements After Treatment with ZFN's SB-728-T

Financial news for SGMO dated on 2013-03-05: Increased Volatility in SGMO as Traded 2,022 April \$10 Puts Over 307 Open Interest; Shares Marking Fresh Session Low

Financial news for SGMO dated on 2013-03-04: Sangamo Biosciences Spokesperson Says HIV Cure in Baby is Great News; Says This is More of a Problem in Developing World than in US

Financial news for SGMO dated on 2013-03-03: HIV Infected Baby 'Cured' with Aggressive Drug Treatment -NYT

Financial news for SGMO dated on 2013-02-28: Lazard Capital Markets Initiates Coverage on Sangamo BioSciences, Inc. at Buy, Announces \$16.00 PT

Financial news for SGMO dated on 2013-02-19: UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Financial news for SGMO dated on 2013-02-19: Burrill Initiates Coverage on Sangamo BioSciences, Inc. at Market Outperform, Announces \$28.00 PT

Financial news for SGMO dated on 2013-02-07: Option Alert: Sangamo Biosciences August 17 Call: 500 Contracts Traded vs 25 Open Interest; Currently \$8.51

Financial news for SGMO dated on 2013-02-06: Sangamo BioSciences, Inc. Reports Q4 EPS of \$(0.07); Revenue of \$8.90M vs \$4.70M Est

Financial news for SGMO dated on 2013-01-11: Stocks Hitting 52-Week Highs

Financial news for SGMO dated on 2013-01-10: Stocks Hitting 52-Week Highs

Financial news for SGMO dated on 2012-12-06: Sangamo BioSciences Says Will Provide Update on ZFP Therapeutics at 5pm

Financial news for SGMO dated on 2012-10-24: Sangamo Guides FY Revenue \$18-20M, Had Seen \$14-18M

Financial news for SGMO dated on 2012-10-24: Sangamo Biosciences Reports Q3 EPS \$-0.11 vs \$-0.14 Est; Revenues \$4.9M vs \$3.80M Est

Financial news for SGMO dated on 2012-09-10: Sangamo BioSciences Announces Presentation of Clinical Data from ZFP Therapeutic(r) for HIV/AIDS at ICAAC 2012

Financial news for SGMO dated on 2012-07-02: UPDATE: Piper Jaffray Downgrades Sangamo BioSciences to Underweight on Limited Clinical Drivers

Financial news for SGMO dated on 2012-07-02: Piper Jaffray Downgrades Sangamo Biosciences from Neutral to Underweight, Maintains PT at \$4

Financial news for SGMO dated on 2012-06-20: UPDATE: GARP Research & Securities Drops Coverage on Sangamo Biosciences on Termination of Neuropathy Treatment Efforts

Financial news for SGMO dated on 2012-03-08: Sangamo Biosciences Trading 3.6% Higher on Heavy Volume; Currently at \$5.14

Financial news for SGMO dated on 2012-03-08: Sangamo Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic(r) for "Functional Cure" of HIV/AIDS

Financial news for SGMO dated on 2012-03-05: Weekly Traders Homework: Small-Caps Correcting (w/ Economic Calendar and Stock Radar)

Financial news for SGMO dated on 2012-02-27: Weekly Traders Homework: Oil Is The Hot Theme (w/ Economic Calendar and Stock Radar)

Financial news for SGMO dated on 2012-02-21: Notable Call Options Activity in Sangamo BioSciences

Financial news for SGMO dated on 2012-02-20: Weekly Traders Homework: Contrarian Indicators Flashing (w/ Economic Calendar and Stock Radar)

Financial news for SGMO dated on 2012-02-17: Sangamo Biosciences Trading 23.7% Higher on Heavy Volume; Currently at \$5.2

Financial news for SGMO dated on 2012-02-08: Sangamo Biosciences Reports Q4 EPS \$(0.12) vs \$(0.12) Est; Revenues \$4.75M vs \$3.41M Est

Financial news for SGMO dated on 2012-02-01: Piper Jaffray Upgrades Sangamo BioSciences to Neutral

Financial news for SGMO dated on 2012-02-01: Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases

Financial news for SGMO dated on 2012-01-09: Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials

Financial news for SGMO dated on 2011-12-13: Wedbush Reiterates Sangamo BioSciences Outperform, \$9 FVE

Financial news for SGMO dated on 2011-12-13: Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic Program in Hemophilia B at American Society for Hematology Meeting

Financial news for SGMO dated on 2011-10-25: Sangamo Biosciences Reports Q3 EPS

\$ (0.18) vs \$ (0.16) Est; Revenues \$1.86M vs \$2.82M Est

Financial news for SGMO dated on 2011-10-13: Sangamo BioSciences Announces Publication in Nature of Gene Correction Strategy for Alpha 1-Antitrypsin Deficiency

Financial news for SGMO dated on 2011-10-03: Market Has Broken Two Critical Levels 10-03-2011

Financial news for SGMO dated on 2011-10-03: Piper Jaffray Lowers PT on Sangamo BioSciences to \$2

Financial news for SGMO dated on 2011-10-03: Notable Call Options Activity in Sangamo BioSciences

Financial news for SGMO dated on 2011-10-03: UPDATE: Sangamo BioSciences Conference Call to Begin at 8:30am

Financial news for SGMO dated on 2011-10-03: Financial Breakfast: Morning News Summary for October 3, 2011

Financial news for SGMO dated on 2011-10-03: Sangamo BioSciences Resumes Trading

Financial news for SGMO dated on 2011-10-03: PREVIEW: Sangamo BioSciences to Resume Trading at 7:30am

Financial news for SGMO dated on 2011-10-03: Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints

Financial news for SGMO dated on 2011-09-30: Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Diabetic Neuropathy Trial Monday 8:30am

Financial news for SGMO dated on 2011-09-18: Sangamo BioSciences Presents Clinical Data from ZFN Therapeutic for HIV/AIDS

Financial news for SGMO dated on 2011-08-30: Notable Call Options Activity in Sangamo BioSciences

Financial news for SGMO dated on 2011-08-23: Notable Call Options Activity in Sangamo BioSciences

Financial news for SGMO dated on 2011-08-03: Options Brief: Sangamo BioSciences

Financial news for SGMO dated on 2011-07-21: Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease Technology

Financial news for SGMO dated on 2011-06-27: Benzingas Top Pre-Market NASDAQ Gainers

Financial news for SGMO dated on 2011-05-23: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for SGMO dated on 2011-04-14: Wedbush Lowers Fair Market Value To \$12 On SGMO

Financial news for SGMO dated on 2011-04-08: Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, SYMX, TPX, GY, SCOK, LIWA, IDIX, HERO, SGMO)

Financial news for SGMO dated on 2011-04-08: Options Brief: Sangamo BioSciences (SGMO)

Financial news for SGMO dated on 2011-04-08: Morning Market Top Percentage Gainers and Losers (CONN, TPX, EXPE, CAAS, QLT, SCOK, IDIX, HERO, SGMO, YONG)

Financial news for SGMO dated on 2011-04-08: Sangamo Announces Pricing of Public Offering of Common Stock at \$4.70 per Share

Financial news for SGMO dated on 2011-04-08: Pre-Market Top Percentage Gainers and Losers (EXPE, STX, NSPI, INTC, IMGN, CONN, SCOK, HERO, IDIX, SGMO, CHBT)

Financial news for SGMO dated on 2011-04-08: Benzinga's Top Pre-Market NASDAQ Losers (HERO, IDIX, XING, SGMO)

Financial news for SGMO dated on 2011-04-08: Stocks To Watch For April 8 (STX, SGMO, TPX, EXPE, LAKE)

Financial news for SGMO dated on 2011-04-07: Sangamo Announces Public Offering Of 6.7M Shares

Financial news for SGMO dated on 2011-02-14: Options Brief: Sangamo BioSciences (SGMO)

Financial news for SGMO dated on 2011-02-14: Calls Purchased on Sangamo BioSciences (SGMO)

Financial news for SGMO dated on 2010-12-16: Sangamo BioSciences Shares Surge 9.6% (SGMO)

Financial news for SGMO dated on 2010-12-02: Benzinga's Top Pre-Market NASDAQ Gainers (KUTV, SGMO, FNSR, WTSLA)

Financial news for SGMO dated on 2010-11-29: Benzinga's Top Pre-Market NASDAQ Gainers (SGMO, AMZN, YHOO, AAPL)

Financial news for SGMO dated on 2010-11-18: Piper Jaffray Maintains Underweight On Sangamo BioSciences (SGMO)

Financial news for SGMO dated on 2010-10-28: Piper Jaffray Maintains Underweight On Sangamo BioSciences (SGMO)

Financial news for SGMO dated on 2010-10-27: Sangamo BioSciences Reports Third Quarter 2010 Financial Results: Loss of \$0.19

Financial news for SGMO dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for SGMO dated on 2009-10-07: Biggest Losers (MERX, AAI, SGMO, CAR, GRS)